On April 28, 2022 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported that it will release first quarter 2022 financial results after the market closes on Thursday, May 5, 2022 (Press release, Xencor, APR 28, 2022, View Source [SID1234613135]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 2583486. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. The webcast will be archived on the company website for 30 days.

On April 28, 2022 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that the results of its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cSCC) have been selected for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held at McCormick Place, in Chicago, June 3-7, 2022 (Press release, Checkpoint Therapeutics, APR 28, 2022, View Source [SID1234613134]). Positive topline data were previously announced in January 2022, and a Biologics License Application (BLA) submission for cosibelimab is planned for later this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma: Results from pivotal cohort
Session: Melanoma/Skin Cancers
Abstract Number for Publication: 9537
Date and Time: Monday, June 6, 2022; 1:15 PM-4:15 PM CDT
Lead Author: Prof. Philip Clingan, Medical Oncologist, Southern Medical Day Care Centre, Australia

About Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1 million cases according to the Skin Cancer Foundation. While most cases are localized tumors amenable to curative resection, approximately 40,000 cases will become advanced and an estimated 15,000 people will die from their disease. In addition to being a life-threatening disease, cSCC causes significant functional morbidities and cosmetic deformities based on tumors commonly arising in the head and neck region and invading blood vessels, nerves and vital organs such as the eye or ear.

About Cosibelimab
Cosibelimab (formerly referred to as CK-301) is a potential best-in-class, high affinity, fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 ("PD-L1") and blocks the PD-L1 interaction with the programmed death receptor-1 ("PD-1") and B7.1 receptors. Cosibelimab’s primary mechanism of action is based on the inhibition of the interaction between PD-L1 and its receptors PD-1 and B7.1, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response. Cosibelimab is potentially differentiated from the currently marketed PD-1 and PD-L1 antibodies through sustained >99% target tumor occupancy to reactivate an antitumor immune response and the additional benefit of a functional Fc domain capable of inducing antibody-dependent cell-mediated cytotoxicity ("ADCC") for potential enhanced efficacy in certain tumor types.

On April 28, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that the Company will release its first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.S. markets (Press release, Curis, APR 28, 2022, View Source,-2022 [SID1234613133]). Management will host a conference call on the same day at 4:30 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317- 5252 from other locations, shortly before 4:30 pm ET. The conference call can also be accessed on the Curis website at www.curis.com in the ‘Investors’ section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

On April 28, 2022 Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), reported the publication of the Company’s 2020 annual financial report (Press release, Onxeo, APR 28, 2022, View Source [SID1234613132]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2021 annual financial report is available to the public on the Company’s website.

On April 28, 2022 PharmaMar Group (MSE: PHM) reported total revenues of €53 million in the quarter ending March 31st 2022, up 4% year-on-year (Press release, PharmaMar, APR 28, 2022, View Source [SID1234613131]). The good performance of the oncology business led to recurring revenues (sales plus royalties), growing by 7% in the first three months of the year to €46 million. Of this, revenues of Zepzelca (lurbinectedin) in Europe under the early access program were €8.7 million, up 1% year-on-year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The good performance of the oncology revenues is also reflected in royalty revenues, which grew by 27% to the end of the first quarter to €11 million .

In the case of non-recurring revenues from licensing agreements, these mainly relate to the revenue recognition from the licensing agreement entered into with Jazz Pharmaceuticals, leading to a recognition of €7.2 million for the quarter, compared with €8 million recognized in the first quarter of the previous year.

During the first three months of the year, R&D expenditure amounted to €19 million, an increase of 29% compared with the first quarter of the previous year, due to the clinical trials under way.

As a result, PharmaMar Group reported an EBITDA of €20.6 million in the first quarter of 2022, 6% higher than in the same period of 2021.

PharmaMar Group generated €36 million in operating cash flow over the period. As a result, PharmaMar Group’s total cash and cash equivalents amounted to €249 million at the end of the first quarter. The Group’s total financial debt was reduced to €44 million, from €46 million at the end of the previous year. As a result, net cash increased by 23%, from €167 million in December 2021 to €206 million to March 31st.

PharmaMar Group reported a net income of €22 million at the end of Q12022, slightly lower than in the same period of 2021.

Results conference call for analysts and investors

PharmaMar will host a conference call for analysts and investors on Friday, April 29th, 2022, at 13:00 (CET). The numbers to connect to the teleconference are: +34 91 901 16 44 (from Spain), +1 646 664 1960 (from the US or Canada) or +44 20 3936 2999 (other countries). Participants’ access code: 250969.

The teleconference and the recording of the webcast can be accessed on PharmaMar’s website by visiting the Events Calendar section of the Company’s website at www.pharmamar.com.

1 As our partner, Jazz Pharmaceuticals, has not yet reported its financial results for the first quarter of 2022, the royalties recorded in the first quarter of this year are an estimation based on our available information.